TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16169791

Group type: EXPERIMENTAL
Intervention: Survey of parents regarding child's asthma history and perceived benefits/barriers to PCP follow-up
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Recent hospitalization, more than one ED visit for asthma in the past year, parent's assessment of 'very severe' asthma, current daily use of a controller medication
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Parental beliefs about the importance of daily asthma medications and understanding causes of asthma attacks
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Reported lack of convenient appointments or prolonged waits in the PCP office
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Multivariable model including clinical factors, parental beliefs, and study intervention
Number of subjects: 278
Study: 11962676

Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5‐fluorouracil (5‐FU), leucovorin, and oxaliplatin (L‐OHP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5‐FU, leucovorin, and L‐OHP
Number of subjects: 0
Study: 10335758

Group type: EXPERIMENTAL
Intervention: AV junction ablation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modulation of AV node conduction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 8926908

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg nocte
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg nocte
Number of subjects: 34
Study: 1888829

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole o.m. (n = 12)
Number of subjects: 24
Study: 6366419

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31060890

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 117
Study: 29769818

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CMR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Drinking to replace all weight loss (DWL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Drinking 'ad libitum' (DAL)
Number of subjects: 11
Study: 27785010

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Indacaterol (IND) 150 μg once daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Glycopyrronium (GLY) 50 μg once daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 μg once daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 182
Study: 24885904

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT) for 16 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Collaborative assessment and management of suicidality-informed supportive psychotherapy for up to 16 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Collaborative assessment and management of suicidality-informed supportive psychotherapy
Number of subjects: 160
Study: 22225733

Group type: EXPERIMENTAL
Intervention: Central trial coordinator in the Netherlands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local study coordinators in Canada
Number of subjects: 0

Group type: COMPARATOR
Intervention: US sites
Number of subjects: 0
Study: 19782267

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate disodium (ATP) at a mean rate of 103 microg/kg/min for 1 hour during reperfusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate disodium (ATP)
Number of subjects: 27
Study: 17210507

Group type: EXPERIMENTAL
Intervention: Sunflower therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 15811926

Group type: EXPERIMENTAL
Intervention: recombinant human (rh) GH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ghrelin analog GHRP-2
Number of subjects: 17

Group type: COMPARATOR
Intervention: saline
Number of subjects: 17
Study: 12234889

Group type: EXPERIMENTAL
Intervention: Lyophilised fluorescein (68 micro g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional fluorescein ophthalmic solution (0.17%)
Number of subjects: 12
Study: 10805546

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 28
Study: 8845292

Group type: EXPERIMENTAL
Intervention: 4g MgSO4.7H2O
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 40
Study: 2353864

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lovastatin plus gemfibrozil
Number of subjects: 13
Study: 7427509

Group type: EXPERIMENTAL
Intervention: Management of early breast cancer
Number of subjects: 2000
Study: 31558739

Group type: EXPERIMENTAL
Intervention: Rice bran supplementation (1-5 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 27485237

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg, oral, 3 times daily for 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25885010

Group type: EXPERIMENTAL
Intervention: Parent training plus stimulant plus risperidone (augmented treatment)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Parent training plus stimulant plus placebo (basic treatment)
Number of subjects: 168
Study: 24499495

Group type: EXPERIMENTAL
Intervention: NRL001 2 g suppositories (7.5, 10, 12.5 or 15 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22034996

Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous ibutilide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study: 19395948

Group type: EXPERIMENTAL
Intervention: 2 doses LAIV
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1 dose LAIV
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1 dose LAIV (year 2)
Number of subjects: 4

Group type: COMPARATOR
Intervention: 2 doses LAIV (year 1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 17595419

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Fitness training (FIT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 97
Study: 15649287

Group type: EXPERIMENTAL
Intervention: ISO (40 mg) tablets
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vitamins C (25 mg) and E (5 mg) tablets
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo tablets (vehicle only)
Number of subjects: 102
Study: 11452938

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 10 Gy to the flank at age 4 years
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 15-24 Gy at a mean age of 55 months
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) doses under 15 Gy at a mean age of 83 months
Number of subjects: 2778

Group type: COMPARATOR
Intervention: Doxorubicin or cyclophosphamide
Number of subjects: 2778
Study: 9855166

Group type: EXPERIMENTAL
Intervention: Arden plate 7 (6.4 cyc/deg)
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Distance Snellen visual acuity
Number of subjects: 3283
Study: 8207741

Group type: EXPERIMENTAL
Intervention: Perindopril plus hydrochlorothiazide (HCTZ) 12.5 mg once daily
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Perindopril plus nifedipine SR 10 mg twice daily
Number of subjects: 524

Group type: COMPARATOR
Intervention: Control group (placebo run-in)
Number of subjects: 524
Study: 2928444

Group type: EXPERIMENTAL
Intervention: High pleasure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low pleasure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High anger
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low anger
Number of subjects: 40
Study: 810098

Group type: EXPERIMENTAL
Intervention: Urokinase‐Heparin combination (2,700,000 CTA units of Urokinase and 240 mg of Heparin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin alone (300 mg Heparin)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Urokinase‐Heparin combination
Number of subjects: 120
Study: 31243228

Group type: EXPERIMENTAL
Intervention: High-concentration insulin glargine (U300G)
Number of subjects: 108
Study: 28662708

Group type: EXPERIMENTAL
Intervention: MPCNL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: URSL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RPLU
Number of subjects: 150
Study: 24824157

Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening with prostaglandin E2
Number of subjects: 827

Group type: COMPARATOR
Intervention: Inpatient cervical ripening with prostaglandin E2
Number of subjects: 827
Study: 23868083

Group type: EXPERIMENTAL
Intervention: Gain settings ranging from -20 to 20 dB in ultrasound measurements.
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Adjustment for gain setting in the METEOR study sample.
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Age and sex as determinants of gain settings.
Number of subjects: 325
Study: 22056739

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with cisplatin (30 mg/m² weekly during RT)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 230
Study: 19748798

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (eicosapentaenoic acid, 0.96g/day, and docosahexaenoic acid, 0.6g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 0
Study: 16569546

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12756094

Group type: COMPARATOR
Intervention: 0.05% clobetasol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus
Number of subjects: 20
Study: 10958144

Group type: EXPERIMENTAL
Intervention: CAI group (computer-assisted instruction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-CAI group (control)
Number of subjects: 100
Study: 9071201

Group type: EXPERIMENTAL
Intervention: Indobufen (400 mg per day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg per day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 71
Study: 8369985

Group type: EXPERIMENTAL
Intervention: Walking at a speed that kept the exercise heart rate above the anaerobic threshold (group H: n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Walking at a speed that kept the exercise heart rate below the anaerobic threshold (group M: n = 9)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (group C: n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exercise groups (group H and group M)
Number of subjects: 33
Study: 3505530

Group type: EXPERIMENTAL
Intervention: 25 mg/kg of monosodium glutamate (MSG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium chloride (equimolar to MSG)
Number of subjects: 12
Study: 29421837

Group type: EXPERIMENTAL
Intervention: AHPLT group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Semitendinosus group
Number of subjects: 124
Study: 27049290

Group type: EXPERIMENTAL
Intervention: Head cooling
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 196
Study: 25011439

Group type: EXPERIMENTAL
Intervention: OxMdG (oxaliplatin, 5-fluorouracil, and folic acid) with SIRT (Selective Internal Radiation Therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OxMdG (oxaliplatin, 5-fluorouracil, and folic acid) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OxMdG with SIRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: OxMdG alone
Number of subjects: 0
Study: 21902854

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT) - 8 sessions of 1 hour each
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 18
Study: 20816301

Group type: EXPERIMENTAL
Intervention: Distally displaced premolars (DDP) group (n=100)
Number of subjects: 2811

Group type: COMPARATOR
Intervention: Control group (n=500)
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: PDC-DDP group (experimental group 2)
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: Experimental groups 1 and 2
Number of subjects: 2811
Study: 18795656

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 36
Study: 17012105

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 24

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 24
Study: 12952774

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No music or other relaxation techniques
Number of subjects: 0
Study: 11084174

Group type: EXPERIMENTAL
Intervention: Transcervical analgesia with 75 mg of bupivacaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Topical application of 75 mg of bupivacaine to the fallopian tubes
Number of subjects: 61
Study: 9080525

Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR with rate drop sensing
Number of subjects: 284

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 284
Study: 8227469

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times a day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg twice a day
Number of subjects: 97
Study: 3485068

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 29744762

Group type: EXPERIMENTAL
Intervention: Pattern visually evoked potentials (VEP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity assessments
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Retinal nerve fiber layer (RNFL) thickness measurement
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Macular thickness and volume measurements
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Visual field tests
Number of subjects: 19
Study: 29787547

Group type: EXPERIMENTAL
Intervention: Interrupted fascial closure (IFC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Continuous fascial closure (CFC)
Number of subjects: 136
Study: 26668251

Group type: EXPERIMENTAL
Intervention: 40 mg balugrastim
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 50 mg balugrastim
Number of subjects: 256

Group type: COMPARATOR
Intervention: 6 mg pegfilgrastim
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: balugrastim
Number of subjects: 256
Study: 24568271

Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Programme and Home Parent Support
Number of subjects: 126

Group type: COMPARATOR
Intervention: Incredible Years Parent Programme alone
Number of subjects: 126
Study: 22911148

Group type: EXPERIMENTAL
Intervention: LRYGBP+FR
Number of subjects: 24

Group type: COMPARATOR
Intervention: LRYGBP
Number of subjects: 24
Study: 19862815

Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice daily plus subcutaneous IFN 0.5 million U (MU) twice daily
Number of subjects: 80
Study: 17359400

Group type: EXPERIMENTAL
Intervention: ProSeal LMA (PLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study: 15182266

Group type: EXPERIMENTAL
Intervention: Combination treatment (antibiotics, ribavirin, corticosteroids, pulsed methylprednisolone if needed)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 88
Study: 11680329

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (20 μg, increased to 40 μg after three doses, administered every 2 hours)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 25
Study: 9675624

Group type: EXPERIMENTAL
Intervention: 25 mg chlorthalidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 120 mg propranolol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mg per day bopindolol
Number of subjects: 100
Study: 7926702

Group type: EXPERIMENTAL
Intervention: Coping through avoidance or seeking social support
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Marital interaction (patient-rated)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Marital interaction (spouse-rated)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Depression levels
Number of subjects: 92
Study: 2512630

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with amino acids (1000 ml of Vamin 14g N/l)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parenteral nutrition without amino acids
Number of subjects: 10
Study: 28619129

Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate 2.5-mg tablet (test)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Levamlodipine besylate 2.5-mg marketed counterpart (reference)
Number of subjects: 50
Study: 31916092

Group type: EXPERIMENTAL
Intervention: Surgical oncologists
Number of subjects: 289

Group type: COMPARATOR
Intervention: Non-surgical oncologists
Number of subjects: 289
Study: 31464581

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50, 100, or 200 mg
Number of subjects: 4439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 4439
Study: 28459835

Group type: EXPERIMENTAL
Intervention: Self-selected intensity exercise (SS-EX)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (MOD-EX)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Entertainment-themed video game (ET-VG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fitness-themed video game (FT-VG)
Number of subjects: 23
Study: 25209926

Group type: EXPERIMENTAL
Intervention: 200 mg daily of self-administered vaginal progesterone
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 22936007

Group type: EXPERIMENTAL
Intervention: Tideglusib (400, 600, 800, 1,000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21349646

Group type: EXPERIMENTAL
Intervention: Polyhexanide containing bio-cellulose dressing (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (group A)
Number of subjects: 60
Study: 19906334

Group type: EXPERIMENTAL
Intervention: Medical termination of pregnancy (MTOP) - mifepristone 200 mg orally followed by misoprostol 36-48 hours later
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Surgical termination of pregnancy (STOP) - misoprostol 400 micrograms 2 hours before procedure, performed under general anaesthesia using vacuum aspiration
Number of subjects: 1877
Study: 16952509

Group type: EXPERIMENTAL
Intervention: Normal spermatogenesis (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maturation arrest (n = 5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sertoli cell‐only syndrome (n = 4)
Number of subjects: 17
Study: 14762776

Group type: EXPERIMENTAL
Intervention: Scheduled infliximab 10 mg/kg
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Scheduled infliximab 5 mg/kg
Number of subjects: 573

Group type: COMPARATOR
Intervention: Episodic infliximab (placebo)
Number of subjects: 573
Study: 11780880

Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Left prefrontal rTMS
Number of subjects: 12
Study: 9137509

Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with medroxyprogesterone acetate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with prednisolone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cox's proportional hazard model
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Landmark method (3-month)
Number of subjects: 102
Study: 8106223

Group type: EXPERIMENTAL
Intervention: 6mg buccal prochlorperazine one hour before surgery
Number of subjects: 52
Study: 3661963

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31376290

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling (US)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Air polishing (AP)
Number of subjects: 17
Study: 28715811

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (3-month scheduled followed by 9-month pro re nata)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 18
Study: 25430728

Group type: EXPERIMENTAL
Intervention: Postoperative intermediate care
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard surgical ward care
Number of subjects: 18
Study: 23621388

Group type: EXPERIMENTAL
Intervention: Matrix rhythm therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 15
Study: 21566425

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HF HD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional hemodialysis (Control)
Number of subjects: 42
Study: 19076173

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (TP) using low molecular weight heparins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New classes of oral anticoagulants (e.g., dabigatran, rivaroxiban)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NICE guidelines for VTE prevention
Number of subjects: 0